论文信息 - Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

Real-life data concerning dupilumab effectiveness and safety in adolescents (≥12 to <18 years) with moderate-to-severe atopic dermatitis (AD) are rarely reported.1 In the adolescent phase III randomized, placebo-controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open label extension (LIBERTY AD PED-OLE)3 dupilumab showed significant signs and symptoms improvement at week-16, with a good safety profile. Herein, we report our real-life experience on AD adolescents treated with dupilumab.

[1] I. Zalaudek,et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry , 2020, Allergy.

[2] G. Fabbrocini,et al. Dupilumab and COVID‐19: What should we expect? , 2020, Dermatologic therapy.

[3] F. Aubin,et al. Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series , 2019, Acta dermato-venereologica.

[4] John D. Davis,et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis , 2019, JAMA dermatology.

[5] N. Stahl,et al. Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension , 2019, The British journal of dermatology.